Tyrvaya (Varenicline Nasal Spray): Novel Treatment for Dry Eye Disease

Tyrvaya: First FDA-Approved Nasal Spray for Dry Eye Disease

Important Correction: Tyrvaya is a nasal spray containing varenicline (a nicotinic acetylcholine receptor agonist), not a cyclosporine emulsion. It is the first FDA-approved nasal spray for the signs and symptoms of dry eye disease (DED) in adults.

Mechanism of Action

Varenicline activates nicotinic acetylcholine receptors (nAChRs) on the trigeminal nerve endings in the nasal mucosa. This stimulates the nasolacrimal reflex arc, increasing basal tear production via parasympathetic outflow to the lacrimal functional unit (lacrimal gland, goblet cells, meibomian glands). This neural pathway enhances all three layers of the tear film: aqueous, mucin, and lipid.

Clinical Efficacy (ONSET-1 and ONSET-2 Trials)

  • Significant improvement in Schirmer's test (tear production) at 4 weeks
  • Significant improvement in Eye Dryness Score (EDS) – patient-reported symptom
  • Rapid onset: some patients report improvement within days
  • Efficacy sustained through 12 weeks

Dosing and Administration

  • Dose: One spray (0.03 mg) in each nostril twice daily (~12 hours apart)
  • Technique: Prime before first use; insert tip into nostril, aim toward lateral wall, spray while breathing gently; do not sniff hard
  • Concomitant Use: No need to wait before using other nasal products (but separate administration if possible)

Common Side Effects (≥5%)

  • Sneezing (most common, ~80% – usually transient, decreases with continued use)
  • Cough, throat irritation
  • Nasal discomfort, epistaxis
  • Headache

Advantages Over Traditional Topical Therapies

  • Non-ocular route: avoids ocular surface irritation, preservative exposure, and post-instillation blur
  • Stimulates natural tear production (all three layers) rather than supplementing
  • No immunosuppressive effects (unlike cyclosporine, lifitegrast)
  • Convenient nasal delivery

Precautions and Contraindications

  • Not studied in patients <18 years, pregnancy, or lactation
  • Caution with active nasal/sinus conditions (recent surgery, trauma, ulcer)
  • No known drug interactions (minimal systemic absorption)
  • Not for acute ocular infections or inflammation

Place in Therapy

  • Adjunct or alternative for patients intolerant of topical drops
  • Especially useful for aqueous-deficient DED with low Schirmer's test
  • Can combine with artificial tears, cyclosporine, lifitegrast, punctal plugs
  • Cost/access: prior authorization common; patient support programs available

Tyrvaya represents a novel neurostimulation approach to dry eye disease. Discuss with your eye care provider if it fits your dry eye subtype and treatment goals.

Eye & Vision Disorders - Related Articles